Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 5 5 W ELECTROLYTES versus TRAVASOL 8 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 5 5 W ELECTROLYTES versus TRAVASOL 8 5 W O ELECTROLYTES.
TRAVASOL 5.5% W/ ELECTROLYTES vs TRAVASOL 8.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
TRAVASOL 8.5% W/O ELECTROLYTES provides amino acids for protein synthesis, serving as a source of nitrogen and essential amino acids to support anabolism and prevent catabolism in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
Intravenous infusion; 500 mL to 1 L per day, administered at a rate of 100-200 mL/hour. Dosage depends on protein and calorie requirements, typically 0.8-1.5 g/kg/day of amino acids.
None Documented
None Documented
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Not applicable as a single value; amino acids have variable half-lives (minutes to hours) depending on individual metabolic demand and plasma concentration; continuous infusion achieves steady state rapidly.
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Primarily eliminated via metabolic pathways (hepatic deamination and transamination) with nitrogenous waste excreted renally as urea; negligible biliary/fecal excretion of unchanged amino acids.
Category C
Category C
Amino Acid Solution
Amino Acid Solution